[ U.S. CDMRP – Lung Cancer Research Program Investigator Initiated Translational Research Award ]
Event details
| Date | 06.05.2020 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the Lung Cancer Research Program (LCRP) Awards. The LCRP Investigator Initiated Translational Research Award supports translational research that will develop promising ideas in lung cancer into clinical applications. This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:
In addition, all applications for LCRP funding must specifically address at least one of the Areas of Emphasis as directed by Congress and have direct relevance to military health. The FY20 LCRP Topic Areas are listed at the end of this announcement.
Funding: max. $400’000
Duration: 2 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. PI applicants must be independent investigators at or above the level of Assistant Professor (or equivalent).
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a preproposal narrative, and a list of collaborators and key personnel as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 06-May-2020, 5:00 p.m. EST
Full Application Deadline: 29-Jul-2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number: W81XWH-20-LCRP-IITRA
Further information
FY20 Areas of Emphasis
- Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts.
- Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission.
- Correlative studies that are associated with an open/ongoing or completed clinical trial and projects that develop endpoints for clinical trials.
In addition, all applications for LCRP funding must specifically address at least one of the Areas of Emphasis as directed by Congress and have direct relevance to military health. The FY20 LCRP Topic Areas are listed at the end of this announcement.
Funding: max. $400’000
Duration: 2 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. PI applicants must be independent investigators at or above the level of Assistant Professor (or equivalent).
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a preproposal narrative, and a list of collaborators and key personnel as suggested on the platform. Full applications (by invitation) will be made via a Grants.gov workspace. Full application packages can be downloaded from Grants.gov at any time.
Pre-Application Deadline: 06-May-2020, 5:00 p.m. EST
Full Application Deadline: 29-Jul-2020, 11:59 p.m. EST
Grants.gov Funding Opportunity Number: W81XWH-20-LCRP-IITRA
Further information
- To see the program announcement, navigate to the search page on Grants.gov and search for the Opportunity Number W81XWH-20-LCRP-IITRA
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
FY20 Areas of Emphasis
- Identify innovative strategies for prevention of the occurrence of lung cancer.
- Identify innovative strategies for the screening and early detection of lung cancer.
- Understand the molecular mechanisms of initiation and progression to lung cancer.
- Understand contributors to lung cancer development other than tobacco.
- DoD FY20 Lung Cancer Investigator-Initiated Translational Research Award 4
- Identify innovative strategies for the treatment of lung cancer.
- Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
- Develop or optimize prognostic or predictive markers to assist with therapeutic decision-making.
- Understand mechanisms of resistance to treatment (primary and secondary).
- Identify innovative strategies for lung cancer care delivery (disparities/clinical management/ surveillance/symptom management).
Practical information
- General public
- Free